Mylan shareholders revolt, say directors’ greed has gone too far

Enlarge / Heather Bresch, chief executive officer of Mylan NV, is questioned by lawmakers over why the company raised the price of the life-saving injection to $ 600 for a two-pack from $ 57 a shot. (credit: Getty | Andrew Harrer/Bloomberg )

A group of disgruntled Mylan investors launched a campaign late Tuesday to block the re-election of six directors over their exorbitant—and increasing—compensation. That’s according to a report in the Wall Street Journal.

In a letter sent to fellow shareholders, the group lambasted hefty bonuses and salary increases that came as the company faced backlash for the skyrocketing price of its life-saving EpiPen devices. Such outrage is likely to continue given that a new government report released today suggests that Mylan overcharged taxpayers $ 1.27 billion dollars for EpiPens over 10 years.

The ongoing EpiPen pricing scandal has caused Mylan “significant reputational and financial harm,” the investors complained. Yet directors continued to be rewarded. The investors were particularly critical of Chairman Robert Coury, who received more than $ 160 million in compensation in 2016 and will receive a $ 1.8 million per year “cash retainer” as part of a deal made with Mylan last year. Trade publication FiercePharma reports that Coury is the highest-paid executive in the drug industry.

Read 4 remaining paragraphs | Comments

Ars Technica

Post Author: martin

Martin is an enthusiastic programmer, a webdeveloper and a young entrepreneur. He is intereted into computers for a long time. In the age of 10 he has programmed his first website and since then he has been working on web technologies until now. He is the Founder and Editor-in-Chief of BriefNews.eu and PCHealthBoost.info Online Magazines. His colleagues appreciate him as a passionate workhorse, a fan of new technologies, an eternal optimist and a dreamer, but especially the soul of the team for whom he can do anything in the world.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.